A phase 3 trial evaluates the efficacy of mezigdomide plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in ...

Despite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models ...

Mezigdomide plus carfilzomib/dexamethasone halved progression/death risk (HR 0.48), extending median PFS to 18.0 months versus 8.3 months with Kd. Enrollment captured ...

Interim analysis demonstrated superior progression-free survival with MeziKd versus carfilzomib/dexamethasone in anti-CD38– and lenalidomide-exposed relapsed ...

Mezigdomide plus lenalidomide improved progression-free survival and displayed a manageable and predictable safety profile.

The lead investigator for SUCCESSOR-2 discusses the potency of a potential successor to pomalidomide in treatment of multiple myeloma, with survival outcomes that rival CAR T-cell therapy. The ...

Mezigdomide plus carfilzomib and dexamethasone improves progression free survival in patients with relapsed or refractory multiple myeloma. Positive interim results were announced from a phase 3 trial ...

Suggested remit: To appraise the clinical and cost effectiveness of mezigdomide with dexamethasone and carfilzomib within its marketing authorisation for treating relapsed or refractory multiple ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of CELMoD (cereblon E3 ligase ...

frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). This is an ASCO Meeting Abstract from ...